Krystal Biotech (KRYS) EBIAT: 2021-2025
Historic EBIAT for Krystal Biotech (KRYS) over the last 5 years, with Sep 2025 value amounting to $79.4 million.
- Krystal Biotech's EBIAT rose 192.00% to $79.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $198.9 million, marking a year-over-year increase of 279.80%. This contributed to the annual value of $89.2 million for FY2024, which is 715.58% up from last year.
- As of Q3 2025, Krystal Biotech's EBIAT stood at $79.4 million, which was up 107.04% from $38.3 million recorded in Q2 2025.
- Krystal Biotech's 5-year EBIAT high stood at $80.7 million for Q3 2023, and its period low was -$50.0 million during Q1 2022.
- For the 3-year period, Krystal Biotech's EBIAT averaged around $23.0 million, with its median value being $27.2 million (2024).
- Its EBIAT has fluctuated over the past 5 years, first crashed by 215.99% in 2022, then soared by 3,734.01% in 2025.
- Quarterly analysis of 5 years shows Krystal Biotech's EBIAT stood at -$21.8 million in 2021, then tumbled by 46.99% to -$32.1 million in 2022, then skyrocketed by 127.12% to $8.7 million in 2023, then skyrocketed by 423.23% to $45.5 million in 2024, then skyrocketed by 192.00% to $79.4 million in 2025.
- Its last three reported values are $79.4 million in Q3 2025, $38.3 million for Q2 2025, and $35.7 million during Q1 2025.